Serum biomarker and study group
|
Level changesa
|
---|
Δδ day 14 of cycle 1 - baseline
|
P value
|
Δδ day 1 of cycle 2 - baseline
|
P value
|
Δδ day 1 of cycle 3 - baseline
|
P value
|
---|
VEGF-A
|
Sunitinib
|
-0.6816 (1.43)
|
0.017
|
-0.1393 (1.83)
|
0.831
|
0.1111 (1.26)
|
0.975
|
Placebo
|
-0.3134 (1.24)
|
0.472
|
-0.7184 (1.32)
|
0.033
|
-1.1177 (1.92)
|
0.062
|
sVEGFR2
|
Sunitinib
|
-0.0648 (0.17)
|
0.012
|
-0.0854 (0.12)
|
0.006
|
-0.0727 (0.14)
|
0.078
|
Placebo
|
-0.0086 (0.12)
|
0. 222
|
-0.0216 (0.10)
|
0.472
|
0.0306 (0.20)
|
0.910
|
VEGF-D
|
Sunitinib
|
0.2476 (0.26)
|
<0.001
|
0.1038 (0.27)
|
0.131
|
0.0914 (0.20)
|
0.133
|
Placebo
|
-0.1093 (0.66)
|
0.616
|
-0.0094 (0.19)
|
0.811
|
-0.1061 (0.25)
|
0.281
|
SDF-1α
|
Sunitinib
|
0.0914 (0.47)
|
0.756
|
0.2912 (0.92)
|
0.730
|
-
|
-
|
Placebo
|
-0.0827 (0.93)
|
0.820
|
0.3572 (0.85)
|
0.041
|
-
|
-
|
- aData are presented as mean (SD). P < 0.05 marked in boldface and considered significant using paired Wilcoxon test